sm-p80
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 23, 2022 (NCT05292391)
Timeline
Indications
Mechanism of action
- Schistosoma mansoniImmunity, active
Schistosoma mansoni immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05999825 | Phase 2 | Sep 30, 2024 | Leiden University, Medical Research Council-UVRI Uganda Research Unit on AIDS, Texas Tech University |
| NCT05762393 | Phase 1 | Aug 1, 2023 | International Vaccine Institute |
| NCT05292391 | Phase 1 | May 23, 2022 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| International Vaccine Institute | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Leiden University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Medical Research Council-UVRI Uganda Research Unit on AIDS | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2022 |
| Texas Tech University | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1